Immunization with two recombinant Bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice
Authors:
- 3 February 2010
- journal article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 136 (9) , 1359-1367
Abstract
Mucin-1 (MUC1) is a breast tumor-associated antigen. However, clinical trials with MUC1 showed that, with respect to its expression levels, MUC1 is a relatively poor immunogen in human beings. Evidence showed that MUC1-specific immunodominant B and T cell epitopes are derived from the variable-number tandem repeat (VNTR) region. Therefore, immunotherapy that targets multiple VNTRs may induce anti-MUC1 immune responses. GM-CSF has been shown to increase the percentage and activity of antigen-presenting cells. In this study, we constructed two recombinant Bacillus Calmette-Guérin (BCG) vaccines that combine the expression of multiple tandem repeats of MUC1 and CSF. The effect of two novel breast cancer vaccines (rBCG-MVNTR4-CSF and rBCG-MVNTR8-CSF) on the growth of breast tumor on hu-PBL-SCID mice was evaluated. We coupled VNTRs (4 and 8) of MUC1 with GM-CSF (MVNTR4-CSF and MVNTR8-CSF). The MVNTR4-CSF and MVNTR8-CSF were inserted into the pDE22 plasmid and transformed into competent BCG by electroporation. The effect of both BCG vaccines on the growth of breast tumor on hu-PBL-SCID mice was evaluated. The growth of MUC1-positive breast tumors from hu-PBL-SCID mice immunized with two vaccines was significantly inhibited. rBCG-MVNTR4-CSF and rBCG-MVNTR8-CSF vaccines may be good candidates for breast tumor immunotherapy.Keywords
This publication has 27 references indexed in Scilit:
- Pre-clinical safety evaluation of heat shock protein 65–MUC1 peptide fusion proteinRegulatory Toxicology and Pharmacology, 2007
- Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancersExpert Review of Vaccines, 2005
- Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancerCancer Immunology, Immunotherapy, 2004
- MUC1 and the MUCs: A Family of Human Mucins with Impact in Cancer BiologyCritical Reviews in Clinical Laboratory Sciences, 2004
- Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancerThe Journal of Gene Medicine, 2003
- MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccinesCancer Immunology, Immunotherapy, 2000
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- New use of BCG for recombinant vaccinesNature, 1991
- Recombinant BCG as a candidate oral vaccine vectorResearch in Microbiology, 1990
- A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM‐3 is selectively exposed in a range of primary carcinomasInternational Journal of Cancer, 1989